Dyslipidemi

Why choose PRALUENT®?
The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2


Prevent the Event
Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.1

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice
A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Lipid management in patients with diabetes mellitus
Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.



Leave site modal
Du er i ferd med å forlate campus.sanofi/no. Sanofi er ikke ansvarlig for innholdet på dette eksterne Nettstedet.
Jobber du innen helsevesenet?
Denne nettsiden inneholder informasjon som er kun for helsepersonell som lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, samt studenter i disse fag.